- Imatinib mesylate-induced interstitial lung disease in a patient with prior history of Mycobacterium tuberculosis infection
-
Lee NR, Jang JW, Kim HS, Yhim HY
- KMID: 2366019
- Korean J Intern Med.
- 2015 Jul;30(4):550-553.
- doi: 10.3904/kjim.2015.30.4.550
No abstract available. -
- CITED
-
- Close
- SHARE
-
- Close
- Bowel Perforation after Erlotinib Treatment in a Patient with Non-Small Cell Lung Cancer
-
Cheon YH, Kim MJ, Kang MG, Kim HJ, Lee SS, Kim CY, Jeon DH, Kim YE, Lee GW
- KMID: 1728007
- Yonsei Med J.
- 2011 Jul;52(4):695-698.
- doi: 10.3349/ymj.2011.52.4.695
Erlotinib is accepted as a standard second-line chemotherapeutic agent in patients with non-small cell lung cancer who are refractory or resistant to first-line platinum-based chemotherapy. There has been no previous... -
- CITED
-
- Close
- SHARE
-
- Close
